# PDGFR in gastrointestinal stromal tumour

1 EU-approved indication in gastrointestinal stromal tumour needs a PDGFR result: avapritinib (advanced).

## Approved indications

### PDGFRA mutation

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Avapritinib](https://oncolabels.com/drugs/avapritinib) (Ayvakyt) | PDGFRA D842V | Monotherapy | Advanced | - |

## Label wording

- **Avapritinib** (Ayvakyt), Gastrointestinal stromal tumour, advanced: “AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/gastrointestinal-stromal-tumour/pdgfr